These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25457016)

  • 21. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
    Cruz F
    Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
    [No Abstract]   [Full Text] [Related]  

  • 22. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
    Gong M; Dong W; Huang G; Gong Z; Deng D; Qiu S; Yuan R
    Curr Med Res Opin; 2015; 31(9):1781-92. PubMed ID: 26211817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
    Alcántara-Montero A
    Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
    J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Overactive bladder in patients with infravesical obstruction caused by prostatic adenoma].
    Aliaev IuG; Gadzhieva ZK; Petrovskiĭ NV
    Urologiia; 2010; (6):10-5. PubMed ID: 21427986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination therapy of benign prostate syndrome/lower urinary tract symptoms].
    Madersbacher S
    Urologe A; 2013 Feb; 52(2):212-8. PubMed ID: 23340696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Wein AJ
    J Urol; 2014 Mar; 191(3):739. PubMed ID: 24522051
    [No Abstract]   [Full Text] [Related]  

  • 31. Cognitive and mood side effects of lower urinary tract medication.
    Muderrisoglu AE; Becher KF; Madersbacher S; Michel MC
    Expert Opin Drug Saf; 2019 Oct; 18(10):915-923. PubMed ID: 31373245
    [No Abstract]   [Full Text] [Related]  

  • 32. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Aging Male; 2015 Mar; 18(1):44-8. PubMed ID: 25136746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials: Combination therapy effective for treating male storage symptoms.
    Clyne M
    Nat Rev Urol; 2013 Sep; 10(9):496. PubMed ID: 23958830
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study.
    Hsiao SM; Chang TC; Lin HH
    Maturitas; 2019 Aug; 126():11-17. PubMed ID: 31239111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.
    Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ
    Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of antimuscarinics in patients with LUTS-BPH and OAB symptoms: clinical expertise and resistance to lose the fear to urinary retention risk].
    Ruiz Cerdá JL
    Actas Urol Esp; 2008; 32(10):957-60. PubMed ID: 19143285
    [No Abstract]   [Full Text] [Related]  

  • 39. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.